Navigation Links
Neurocrine Biosciences Reports Third Quarter 2010 Results
Date:10/28/2010

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2010.

For the third quarter of 2010, the Company reported net income of $3.3 million, or $0.06 per share, compared with a net loss of $8.2 million, or $0.21 per share, for the same period in 2009. For the nine months ended September 30, 2010, the Company reported a net loss of $10.5 million, or $0.20 per share, as compared to a net loss of $43.1 million, or $1.11 per share, for the same period last year.

The Company's balance sheet on September 30, 2010 reflected total assets of $149.9 million, including cash, investments and receivables of $140.4 million.

"The financial impact of our two recent collaboration agreements with Abbott and Boehringer Ingelheim is evident in these third quarter financial results and the cash and investments position of Neurocrine," said Timothy P. Coughlin, Chief Financial Officer of Neurocrine Biosciences. "We will continue the fiscal discipline that has been ingrained in the Company over the past three years, while advancing our lead clinical programs; elagolix, VMAT2 and Urocortin 2 and bringing new clinical candidates forward from our research and discovery platform."

Revenues for the third quarter of 2010 were $14.4 million, compared to $0.7 million for the same period in 2009. Revenues for the nine months ended September 30, 2010 were $19.8 million, compared with $2.2 million for the same period in 2009. The increase in revenue is due to our recently executed collaboration agreements with Abbott and Boehringer Ingelheim, for our GnRH (elagolix) and GPR119 programs, respectively. During the third quarter of 2010, we recognized revenue of $8.5 million from amortization of up-front license fees and $5.2 million resulting from internal and external research and d
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... , Sept. 16, 2014 Surgeons at ... describe in a case report the first successful use ... a 13- year-old boy with failing Fontan circulation to ... he was 3 years old, the patient received a ... as functional single ventricle. "The Fontan operation is the ...
(Date:9/16/2014)... Research and Markets has ... Devices Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth ... laparoscopic devices. The report provides a ... applications and industry chain structure. The laparoscopic devices ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Global Laparoscopy Devices Industry Report 2014 2
... 2, 2011 Floridians turned in nearly 5,500 pounds ... pharmacies and law enforcement offices throughout the state during ... more than doubling the amount dropped off at 38 ... Back Day, the National Association of Drug Diversion ...
... 2, 2011 What do Robert DeNiro, Hugo Chavez, Rudy ... Mandela, Colin Powell, Frank Zappa, Telly Savalas, Bill Bixby and ... answer is prostate cancer, then you would be correct. ... all diagnosed and successfully treated.  Chavez, the President of Venezuela, ...
Cached Medicine Technology:NADDI and the C.A.R.E.S. Alliance Co-Sponsor Successful Drug Take Back Day 2
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... therapy as part of breast conservation is the ... positive (HR+) invasive breast cancer. A new study ... shows that combination may not be necessary for ... The results, which Fox Chase researchers presented at ... Meeting on Sunday, September 14, suggest that low-risk ...
(Date:9/16/2014)... Programs and policies that promote health and disease ... in savings for the US health system, according to ... spur these types of improvements, the National Quality Forum ... across the country to field test the NQF Action ... designed to assist groups working together to improve health ...
(Date:9/16/2014)... Silver Spring, Md. (PRWEB) September 16, 2014 ... University of Colorado Anschutz Medical Campus and Children’s ... 2014. PHA is the country’s leading pulmonary hypertension association ... hypertension (PH) – a disease of the lungs that affects ... heart failure. Without treatment, mean survivability is only 2.8 years. ...
(Date:9/16/2014)... By Tara Haelle ... -- A new blood test is the first objective scientific ... claims. The test measures the levels of nine genetic ... test could also determine who will respond to cognitive behavioral ... depression, and could show whether the therapy worked, Northwestern University ...
Breaking Medicine News(10 mins):Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... major medical advances improved survival , TUESDAY, ... has reduced the death rate for patients hospitalized for ... deal with these daily emergencies, a nationwide study finds. ... for Medicare patients treated for heart attacks decreased, from ...
... ACMIC reduces costs ... ... -- Corticon Technologies , the leading provider of Business Rules Management Systems (BRMS) ... gone live with an upgraded claims processing system built on Corticon BRMS. , ,For ...
... , Price of Diabetes ... , , BETHESDA, Md., Aug. ... people with diabetes has been misconstrued during recent health care ... the nation,s leading professional organization of doctors of podiatric medicine ...
... OKLAHOMA CITY, Aug. 18 Almost everyone who lives a long life ... at some point. As more Americans live into their 70s and ... tips that may delay onset, and how to decide when it is time ... August is Cataract Awareness Month, and the Oklahoma Academy of Ophthalmology (OAO) encourages ...
... maybe depressed, new U.S. survey of Internet players finds ... video gamer is not the stereotypical adolescent locked to ... a new U.S. survey, are 35-year-old adults, many of ... , The surprising findings also show that the health ...
... ... application called Med Records to Go(tm) , that stores electronic medical ... hospital or medical clinic admissions. Introduced by the Vital Record Corporation ... record and store personal health information and external documents for emergency viewing ...
Cached Medicine News:Health News:Hospitals Reduce Heart Attack Deaths 2Health News:Hospitals Reduce Heart Attack Deaths 3Health News:American Community Mutual Insurance Company (ACMIC) Selects Corticon 2Health News:American Community Mutual Insurance Company (ACMIC) Selects Corticon 3Health News:American Community Mutual Insurance Company (ACMIC) Selects Corticon 4Health News:American Podiatric Medical Association Corrects President's Misstatement on Foot Amputation Costs 2Health News:What Oklahomans Should Know About Cataract Surgery 2Health News:What Oklahomans Should Know About Cataract Surgery 3Health News:Video Gamers Older Than You Think 2Health News:Video Gamers Older Than You Think 3Health News:Video Gamers Older Than You Think 4Health News:"Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing 2Health News:"Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing 3
... cervical spine manipulation. Prevent dental and soft ... effective alternative to X-ray. Light-guided intubation is ... tissues in the neck. This technique takes ... trachea relative to the esophagus. A well-defined, ...
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....
Medicine Products: